oasis-4 semaglutide Novo Nordisk's OASIS 4 Study Validates Daily Oral Pill for Chronic Weight Management 🥼🧪Slide Deck: Efficacy and safety

Tirzepatide activates both GLP-1 and GIP receptors, creating a dual mechanism that may enhance weight loss and glycemic control through additive pathways

An LOMN is a written statement from a healthcare professional explaining why a specific product or service is needed to treat a diagnosed medical condition

Monitoring and Support : Given the complexity of PWS and the potential need for lifelong treatment, a medication like CT-PYY would likely require a support program to monitor patients, manage dosing, and provide education on managing PWS symptoms

Researchers have shown that the number of quit attempts needed during recovery varies by substance and individual circumstances

doi: 10.1038/s44222-022-00016-2 239 OuQPowerRGriffinMD

This means qualified pharmacies can still compound these products until these drugs are removed from the FDAs drug shortage list